IQVIA

IQVIA is a life sciences services and data company headquartered in Durham, North Carolina (NYSE: IQV), formed in 2016 when the contract research firm Quintiles merged with the health data company IMS Health. It is best known for running clinical trials on behalf of drugmakers and for selling commercial and real-world health data and analytics to the pharmaceutical industry. It appears here not as an AI adopter but as an AI vendor to pharma: it sells AI agents and an agentic platform to drug companies, but only through enterprise contracts, with no self-serve access, free tier or published pricing.

Its defining pattern is the data-moat vendor. IQVIA does not build frontier models; it licenses the model and agent stack from NVIDIA and the cloud from Amazon, and sells what no model lab has, which is decades of health data and the trial operations that generate more of it. It markets the result under a trademarked label, Healthcare-grade AI. In January 2025 it announced a strategic collaboration with NVIDIA to build custom foundation models and AI agents trained on its healthcare information. In June 2025 it launched its first agents, aimed at target identification, clinical data review, literature review, market assessment and engagement with healthcare professionals. NVIDIA reported that the clinical data review agent cut that review from seven weeks to as little as two, a figure from the partners rather than an independent study.

In August 2025 it settled litigation with Veeva Systems that dated to 2017, and the two agreed that IQVIA data can be used in Veeva software, including Veeva's AI agents. In December 2025 IQVIA named Amazon Web Services its preferred cloud provider for agentic AI. In February 2026 it agreed to buy five drug discovery sites from a fellow laboratory services company, a deal that included a small-molecule AI platform and pushes IQVIA earlier into research. In March 2026 it launched IQVIA.ai, a unified agentic platform combining its data with NVIDIA's Nemotron models, the NeMo Agent Toolkit, Dynamo and the open-source LangChain framework. The company says it has deployed more than 150 agents across internal teams and client environments, filed more than 100 AI-related patents, and that 19 of the top 20 pharmaceutical companies have begun incorporating its agents, with more agents promised for the fourth quarter of 2026.

The honest framing: IQVIA's value rests on its trial operations and its data, and AI is a lever that makes both easier to sell and cheaper to run. The adoption figures are the company's own and measure breadth rather than depth, since beginning to incorporate an agent is a low bar, and the one efficiency number comes from a partner announcement. It sits on the opposite side of the table from the drugmakers in the catalog. Gilead procures specialists, Merck & Co. built one enterprise platform with Google Cloud and Novo Nordisk runs several vendors at once, while IQVIA is one of the vendors they buy from. Its nearest catalog peer is Tempus AI, which also turns proprietary clinical data into AI products, though Tempus is built around molecular and diagnostic data rather than running trials.